Valproate Prescription Guide for Healthcare Professionals

This guide is intended for healthcare professionals managing girls and women of childbearing potential, as well as male patients of reproductive potential, who are treated with valproate (Depakine). It outlines the prescribing conditions and necessary precautions due to the risks associated with valproate use during pregnancy. The guide emphasizes the teratogenic risks, including congenital malformations and neurodevelopmental disorders, for children exposed to valproate in utero. It details the responsibilities of healthcare professionals in assessing pregnancy potential, conducting pregnancy tests, and counseling patients on effective contraception. The guide also includes specific recommendations for managing patients of different demographics, including minors, and stresses the importance of adhering to the Pregnancy Prevention Program. It provides tools for healthcare professionals, such as risk acknowledgment forms and patient guides, to ensure informed decision-making and risk mitigation throughout treatment.